Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.
Derek J. Jonker(University of Ottawa), Chiang Li(Boston Biomedical (United States)), Rachel Goodwin(University of Ottawa), Rashmi Chugh(University of Michigan), James M. Cleary(Brigham and Women's Hospital), Wei Li(University of California, Irvine), Keith T. Flaherty(Cancer Research Center), Thomas A. Abrams(Dana-Farber Cancer Institute), Charles S. Fuchs(University of Southern California), Youzhi Li(Boston Biomedical (United States)), Matthew Hitron(Boston Biomedical (United States)), Jamileh Jemison(Boston Biomedical (United States)), Scott A. Laurie(Ottawa Hospital), Paul Conkling(Virginia Oncology Associates), Gregory M. Coté(Harvard University), James W. Mier(Hadassah Medical Center), Eunice L. Kwak(Harvard University), William J. Edenfield(Prisma Health), David C. Smith(University of Michigan), Rakesh Goel(Ottawa Hospital)
Cited by 4
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k